| When compared with the first dose, side effects reported after the second dose were milder and reported less frequently | There were no additional side effects in the 345 people who received Vaxzevria in the trial and had previously had COVID-19 |
|---|---|
| As for all medicines, data on the use of Vaxzevria are continuously monitored | Detailed information about this vaccine is available in the , which includes the |
You are therefore advised to be selective about which sections or pages you wish to print.
| Department of Health and Social Care | Lymphadenopathy enlarged lymph nodes , decreased appetite, dizziness, sleepiness, lethargy lack of energy , sweating, abdominal belly pain, itching, rash and urticaria itchy rash may affect up to 1 in 100 people |
|---|---|
| These trials and additional studies will provide information on how long protection lasts, including against new variants of the virus, how well the vaccine prevents severe COVID-19, how well it protects older people, immunocompromised people, children and pregnant women, and whether it prevents asymptomatic cases | "Covid-19: The E484K mutation and the risks it poses" |
Can people with allergies be vaccinated with Vaxzevria? Woo, Jenny Strasburg and Stu October 21, 2020.
18| "A Phase III study to investigate a vaccine against COVID-19" | Although immunocompromised people may not respond as well to the vaccine, there are no particular safety concerns |
|---|---|
| People receiving Vaxzevria may experience more than one side effect at the same time | There were not enough results in older participants over 55 years old to provide a figure for how well the vaccine will work in this group |
Safety measures will be implemented for Vaxzevria in line with the to ensure that new safety information is rapidly collected and analysed.
2